HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases

Zhimeng Cheng; Panpan Lin; Nansheng Cheng

doi:10.3389/fmed.2021.713981

HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases

Front Med (Lausanne). 2021 Oct 4:8:713981. doi: 10.3389/fmed.2021.713981. eCollection 2021.

Authors

Zhimeng Cheng¹, Panpan Lin², Nansheng Cheng¹

Affiliations

¹ Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, China.
² Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.

Abstract

Hepatitis B virus (HBV) infection is a common contributor to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Approximately 10% of people with human immunodeficiency virus (HIV) also have chronic HBV co-infection, owing to shared transmission routes. HIV/HBV coinfection accelerates the progression of chronic HBV to cirrhosis, end-stage liver disease, or hepatocellular carcinoma compared to chronic HBV mono-infection. HBV/HIV coinfection alters the natural history of hepatitis B and renders the antiviral treatment more complex. In this report, we conducted a critical review on the epidemiology, natural history, and pathogenesis of liver diseases related to HBV/HIV coinfection. We summarized the novel therapeutic options for these coinfected patients.

Keywords: clinical treatment; coinfection; hepatitis B virus; human immunodeficiency virus; liver disease.

Publication types

Review